Incidentally, Schlenk et al. showed that the mutational status of the NPM1, FLT3, CEBPa, MLL, and NRAS genes impacted the clinical outcome in a cohort of 872 adults younger than 60 years old with cytogenetically normal AML. This evidence concerns the gene NPM1 and acute myeloid leukemia.